TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02550678
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU is chemotherapeutic agent used to treat various cancers.
Study: NCT00206544
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg daily of adjunctive tamoxifen in oral capsule
Study: NCT00206544
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg daily of adjunctive progesterone in oral capsule
Study: NCT01540253
Drug: PI3K inhibitor BKM120
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01540253
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03469583
Drug: Entecavir 1 MG
Normalized name: entecavir 1 MG
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir self administered tablets, morning, with non carbonated water
Study: NCT03411330
Drug: Hyaluronidase
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Scalp nerves block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum allowed dose 175 mg in group A, Hyaluronidase will be added in group H in a dose of 1500 IU (The minimum and maximum effective doses of hyaluronidase are not known. The doses used range from0.75 IU/ml to 300 IU/ml
Study: NCT03411330
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%)
Study: NCT03411330
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupivacaine (0.5%)
Study: NCT05526690
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000 mg dose of immediate-release metformin
Study: NCT05526690
Drug: CIN-107
Normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg dose of CIN-107
Study: NCT01265615
Drug: Paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: paricalcitol group (6-8 μg daily per os - orally - without special diet)
Study: NCT01265615
Drug: Calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: calcitriol group (2-4 μg daily orally under with dietary restrictions of vitamin D)
Study: NCT01265615
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cholecalciferol group (intake of cholecalciferol with recommended daily allowance equals 1200-2400 IU per day)
Study: NCT02439996
Drug: IVIG (1g/kg,once)
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C patients received IVIG 1g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once.
Study: NCT02439996
Drug: IVIG (1g/kg,twice)
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B patients received IVIG 1g/kg for 2 days continuously. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once.
Study: NCT02439996
Drug: IVIG (2g/kg.once)
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A patients received IVIG 2g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once.
Study: NCT02274181
Drug: Androxal
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00262964
Drug: Niacin
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to Niacin therapy will be treated with Niacin at night for 16 wks to reduce plasma free fatty acid concentrations. The dose of medication will be gradually increased: 500 mg/day during week 1, 1000 mg/day during week 2, 1500 mg/day during week 3, and 2000mg/day during weeks 4-16.
Study: NCT00262964
Drug: fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects randomized to fenofibrate will be treated with 200 mgs per day for eight weeks.
Study: NCT03088670
Drug: Gosogliptin
Normalized name: Gosogliptin
DrugBank: Gosogliptin (DB08382)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg per day, dose titration to 30 mg per day at Week 4 as required Administration: orally
Study: NCT03088670
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 50 mg per day, dose titration to 100 mg per day at Week 4 as required (50 mg twice a day) Administration: orally
Study: NCT03088670
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000 mg per day starting Week 12 (500 mg twice a day), dose titration to 2000 mg per day at Week 16 as required (1000 mg twice a day).~Administration: orally
Study: NCT02552342
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00223197
Drug: Pregnenolone
Normalized name: Pregnenolone
DrugBank: Pregnenolone (DB02789)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00257673
Drug: MEM 1003
Normalized name: MEM 1003
DrugBank: MEM 1003 (DB05547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg twice a day
Study: NCT00257673
Drug: MEM 1003
Normalized name: MEM 1003
DrugBank: MEM 1003 (DB05547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg MEM 1003 twice a day
Study: NCT00257673
Drug: Placebo for MEM 1003
Normalized name: MEM 1003
DrugBank: MEM 1003 (DB05547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice a day
Study: NCT04234672
Drug: TAK-831 Oral Tablet
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-831 tablet.
Study: NCT02613884
Drug: Treatment
Normalized name: Acne Treatment
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006090
Drug: arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00190814
Drug: duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00713479
Drug: Varenicline, then placebo
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects receive MA infusions on certain days first under varenicline (10 days) then under placebo (8 days) after a 14-24 day washout in order to determine study medication safety and tolerability
Study: NCT04269460
Drug: Bupivacaine Hydrochloride 0.25% Injection Solution [MARCAINE]
Normalized name: Bupivacaine Hydrochloride 0.25% Injection Solution [MARCAINE]
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: preoperative ultrasound guided subcostal TAP block and Quadratus lumborum block using 1 ml/kg of Bupivacaine Hydrochloride 0.25%in pediatric patients undergoing pyeloplasty surgeries.
Study: NCT00006027
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006027
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03006679
Drug: Meropenem-Vaborbactam
Normalized name: meropenem-vaborbactam
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: meropenem 2 g and vaborbactam 2 g
Study: NCT03006679
Drug: Piperacillin/Tazobactam
Normalized name: PIPERACILLIN/TAZOBACTAM
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: piperacillin 4 g and tazobactam 0.5 g
Study: NCT00581971
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV, AUC 2.0, weekly for weeks 1 through 7
Study: NCT00581971
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV 30 mg/m2, weekly for weeks 1 through 7
Study: NCT04068831
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg talazoparib daily
Study: NCT04068831
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 800 mg avelumab every 2 weeks
Study: NCT00709527
Drug: Avacincaptad Pegol
Normalized name: Avacincaptad pegol
DrugBank: Avacincaptad pegol (DB15165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravitreal injection
Study: NCT02770222
Drug: Selexipag
Normalized name: Selexipag
DrugBank: Selexipag (DB11362)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two selexipag film-coated tablets of 200 µg as single oral dose (total dose = 400 µg)
Study: NCT02770222
Drug: Gemfibrozil
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil film-coated tablet of 600 mg administered orally b.i.d. from Day 1 to Day 9
Study: NCT02770222
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin film-coated tablet of 600 mg administered orally o.d.from Day 1 to Day 9
Study: NCT00992901
Drug: Exendin-(9-39)
Normalized name: Exendin 4
DrugBank: Avexitide (DB14806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A physiological study to evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion
Study: NCT00992901
Drug: Atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism
Study: NCT01804777
Drug: HCTZ
Normalized name: HCTZ
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCTZ 12.5 mg taken every day for two weeks, along with adherence to specified diet.~On day 14 titrate dose up to HCTZ 25 mg taken every day for two weeks after completion of two week intake of HCTZ 12.5 mg, along with adherence to specified diet
Study: NCT02651753
Drug: CKD-337
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test Drug: CKD-337
Study: NCT03674671
Drug: Intravenous Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 0.5mg/kg IV over 40 minutes, thrice weekly for 3 or 4 weeks. If participant responds, they will receive infusions weekly for one month, once every two weeks for two months, and once every month for three months. Should participant relapse during once monthly dosing, they may return to dosing once every two weeks for the remainder of the study.
Study: NCT00992901
Drug: GLP-1 and GIP
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A physiological study to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones
Study: NCT03864601
Drug: 14C-JNJ-56136379
Normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14C-JNJ-56136379 25 mg dose formulated as a polyethylene glycol (PEG)-based oral solution containing 3,145 kilo Becquerel (kBq) of 14C labeled JNJ-56136379, with a maximal total radiation burden of 1,000 micro Sievert.
Study: NCT03668860
Drug: Dexamethasone 4 mg/ml
Normalized name: dexamethasone 4 MG/ML
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular. Total dose: 1.5 mL (6 mg)
Study: NCT03668860
Drug: Betamethasone 4 mg/ml
Normalized name: betamethasone 4 MG/ML
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular. Total dose: 1.5 mL (6 mg)
Study: NCT03668860
Drug: Dexamethasone Oral Tablet
Normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral. Total dose: 12 Tablets (6 mg)
Study: NCT03668860
Drug: Betamethasone Oral Tablet
Normalized name: betamethasone Oral Tablet
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral. Total dose: 12 Tablets (6 mg)
Study: NCT00713479
Drug: Placebo, then varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects receive MA infusions on certain days first under placebo (10 days) then under varenicline(8 days) after a 14-28 day washout in order to determine study medication safety and tolerability
Study: NCT03725579
Drug: mepivicane hydrochloride
Normalized name: Mepivacaine Hydrochloride
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pain will be assessed during access cavity preparation and instrumentation
Study: NCT03725579
Drug: articane hydrochloride
Normalized name: Articaine Hydrochloride
DrugBank: Articaine (DB09009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pain will be assessed during access cavity preparation and instrumentation
Study: NCT04200235
Drug: Dexmedetomidine hydrochloride nasal spray
Normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the low weight group, 18 subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, 18 subjects will receive a high dose of dexmedetomidine nasal spray.
Study: NCT04200235
Drug: Dexmedetomidine hydrochloride nasal spray blank preparation.
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the low weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.
Study: NCT02336165
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab is administered as an IV infusion over 60 ± 5 minutes Q2W.
Study: NCT02865850
Drug: Vadadustat
Normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Study: NCT02865850
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
Study: NCT03617263
Drug: Saroglitazar Magnesium 4 mg Tablet
Normalized name: pitavastatin
DrugBank: Saroglitazar (DB13115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomly assigned to this group will receive Saroglitazar Magnesium orally once daily for 24 weeks.
Study: NCT02597101
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: background drug
Study: NCT02597101
Drug: saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: background drug
Study: NCT01515826
Drug: Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One ribbon (approximately 1-1.5 cm) administered topically in the conjunctival sac of the study eye three times daily (TID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
Study: NCT01515826
Drug: Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop administered topically in the conjunctival sac of the study eye four times daily (QID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
Study: NCT04414475
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive Selinexor oral tablets.
Study: NCT04414475
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive Dexamethasone oral tablets.
Study: NCT04414475
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Bortezomib SC injection.
Study: NCT02373098
Drug: Fingolimod 0.5 mg
Normalized name: fingolimod 0.5 MG
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 66 relapsing remitting MS (RRMS) patients were recruited. Patients who met all inclusion and none of the exclusion criteria were treated by Fingolimod 0.5 mg.
Study: NCT00984126
Drug: turoctocog alfa
Normalized name: Turoctocog alfa
DrugBank: Turoctocog alfa (DB09109)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
Study: NCT00984126
Drug: turoctocog alfa
Normalized name: Turoctocog alfa
DrugBank: Turoctocog alfa (DB09109)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
Study: NCT04033471
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: epidural needle in the L1-2 or L2-3 space , and using loss of resistance technique udder strict aseptic condition 10 ml of the prepared drug will be given
Study: NCT03379103
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 1 MAC sevoflurane for 15 minutes before the installation of member ischemia by tourniquete
Study: NCT03379103
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive propofol for 15 minutes before the installation of member ischemia by tourniquete
Study: NCT01884740
Drug: SIACI of Erbitux and Bevacizumab
Normalized name: Erbitux
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive a single intra-arterial dose of Cetuximab (200 mg/m\^2) and Bevacizumab (15 mg/kg) via Superselective Intraarterial Cerebral Infusion (SIACI).
Study: NCT02008565
Drug: Loperamide
Normalized name: Loperamide
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomized to the loperamide group will begin with 2mg of loperamide/day. The participant will be administered the Patient Global Symptom Control rating scale (PGSC) to determine dose escalation. Participants who report inadequate control of stool leakage on the PGSC will be instructed to increase the daily dose of loperamide by 2 mg up to a maximum of 8 mg per day (1-4 capsules). Bothersome adverse events and resulting dose reduction will be based exclusively on the result of the Patient Global Tolerability Scale (PGTS). The daily dose will be decreased by 2mg to a minimum of 2mg every other day. If a PGSC score indicates inadequate control of stool leakage combined with a PGTS score indicating bothersome side effects, the participant will discontinue the study medication.
Study: NCT00002654
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04414605
Drug: Gu Ben Hua Yu Fang decoction (Chinese herbal medicine)
Normalized name: Gu
DrugBank: Guanidine (DB00536)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chinese herbal formula (Gu Ben Hua Yu Fang) decoction will be orally administrated twice daily. One pack of Gu Ben Hua Yu Fang will be taken for each time. Chinese herbal medicine (Gu Ben Hua Yu Fang) will not be used on the day of receiving secukinumab injection.
Study: NCT04414605
Drug: Secukinumab Auto-Injector [Cosentyx]
Normalized name: secukinumab Auto-Injector [Cosentyx]
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab will be administered by subcutaneous injection. The required dose (300 mg) is divided into two doses of 150 mg (contained in two separate syringes), which are injected at the same time. The first five doses (each consisting of 2 injections of 150 mg) are given at weekly intervals, with subsequent treatment given monthly (2 injections of 150 mg).
Study: NCT00493831
Drug: nicotine polacrilex, transdermal system or inhaler
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: on label use of Nicotine replacement therapy (NRT)